COMMEDfinalMED38.docx
-
Upload
nirut-srimakam -
Category
Documents
-
view
214 -
download
0
Transcript of COMMEDfinalMED38.docx
-
7/28/2019 COMMEDfinalMED38.docx
1/9
final QM4-14
QM 4
QM []
QM8
]
QM5 - 10
QM6 - 15
QM7+8 - 10
QM9+10+11 - 40 ]
QM12 - 15
QM13 - 5
QM14 - 5
QM10
=0=
QM 5 -
-
]
-
-
7/28/2019 COMMEDfinalMED38.docx
2/9
-
-
-
-
-
-
-
]
QM 6 -
- incident rate ratio
person time at risk
- incident rate [ odd ratio , risk ratio , hazard ratio ]
- case control cohortstudy
case control
cohort study
- cross section descriptive study analytical cross sectional study
-
-
-
7/28/2019 COMMEDfinalMED38.docx
3/9
-
factor
- case controlstudy
recall bias-
crossectional study
- matching
information bias , selection bias , confounding bias
-
selection bias
QM7+8
-
( 5 year survival rate)
type II error-
Inclusion & exclusion criteria-
-
Diclofenac
relative risk [RR]
diclofenac
2
-
7/28/2019 COMMEDfinalMED38.docx
4/9
-
-
]
-
cohort study- subject
compliance-
perprotocal analysis [
]
-
single blinded-
2
]-
recall bias
-
7/28/2019 COMMEDfinalMED38.docx
5/9
QM 9 + 10 + 11
-
-
test
-
outcome
-
-
meta analysis-
heterogenicity test-
oxidant
1 anti oxidant placebo
-
forest plot
- funnel plot- ]
funnel plot-
general search engine-
text book [ ]
- foreground Q
- background Q
- ]
control
-
7/28/2019 COMMEDfinalMED38.docx
6/9
- ] intervention
simvastatin
-
case control [ N of 1 , RCT , systematic review , cohort]-
arrhythmai
strength-
reversibility-
Positive predictive value-
prevalence-
-sensitivity
-specificity-positive predictive value [
]
-negative predictive value [ positive]
-positive likelihood ratio [
]
-negative likelihood ratio
-
positive likelihood
, spec
ratio -
% 100
pretest odd x likelihood = post test odd
post test odd
prevalence = odd / 1+odd
-
7/28/2019 COMMEDfinalMED38.docx
7/9
]
-accuracy = TP+TN/ = [sen x prevalence] + [ spec x (1-prevalence)]
med37
QM10
56. simvastatin
A. General search engine*****( ^^)
B. Research journal database
C. Systematic review
D. UpToDate
E. Textbook
QM 12
QM
-
HIV
-
- inform consent -
- ]
-
= =
-
-
-
-
7/28/2019 COMMEDfinalMED38.docx
8/9
-
well known investigator-
77. )
- HIV
87.
- -()
-*****
-
-
82.
A.
B.
C.
TT
D.
E.
90.
a.reserch value & validity
b.appropiate inclusion & exclusion criteria
c.aceptable benefit risk ratio
d.well-known investigator
-
7/28/2019 COMMEDfinalMED38.docx
9/9
[]
-
-
QM 14
-
outcome-
[
= =]
-
80
]
16-Economic evaluation
-
-
cost effectiveness analysis